Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more
Viatris Inc (VTRS) - Net Assets
Latest net assets as of September 2025: $15.22 Billion USD
Based on the latest financial reports, Viatris Inc (VTRS) has net assets worth $15.22 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.92 Billion) and total liabilities ($22.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.22 Billion |
| % of Total Assets | 40.13% |
| Annual Growth Rate | 16.55% |
| 5-Year Change | -18.81% |
| 10-Year Change | 90.82% |
| Growth Volatility | 42.37 |
Viatris Inc - Net Assets Trend (1985–2024)
This chart illustrates how Viatris Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Viatris Inc (1985–2024)
The table below shows the annual net assets of Viatris Inc from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $18.64 Billion | -8.95% |
| 2023-12-31 | $20.47 Billion | -2.87% |
| 2022-12-31 | $21.07 Billion | +2.83% |
| 2021-12-31 | $20.49 Billion | -10.72% |
| 2020-12-31 | $22.95 Billion | +93.15% |
| 2019-12-31 | $11.88 Billion | -2.33% |
| 2018-12-31 | $12.17 Billion | -8.57% |
| 2017-12-31 | $13.31 Billion | +19.70% |
| 2016-12-31 | $11.12 Billion | +13.84% |
| 2015-12-31 | $9.77 Billion | +198.10% |
| 2014-12-31 | $3.28 Billion | +10.68% |
| 2013-12-31 | $2.96 Billion | -11.80% |
| 2012-12-31 | $3.36 Billion | -4.25% |
| 2011-12-31 | $3.50 Billion | -3.06% |
| 2010-12-31 | $3.62 Billion | +14.95% |
| 2009-12-31 | $3.15 Billion | +12.86% |
| 2008-12-31 | $2.79 Billion | -18.93% |
| 2007-12-31 | $3.44 Billion | +103.17% |
| 2006-12-31 | $1.69 Billion | +114.82% |
| 2005-12-31 | $787.65 Million | -57.33% |
| 2004-12-31 | $1.85 Billion | +11.22% |
| 2003-12-31 | $1.66 Billion | +14.76% |
| 2002-12-31 | $1.45 Billion | +3.14% |
| 2001-12-31 | $1.40 Billion | +23.81% |
| 2000-12-31 | $1.13 Billion | -5.91% |
| 1999-12-31 | $1.20 Billion | +13.57% |
| 1998-12-31 | $1.06 Billion | +42.36% |
| 1997-12-31 | $744.50 Million | +12.85% |
| 1996-12-31 | $659.70 Million | +7.02% |
| 1995-12-31 | $616.40 Million | +27.70% |
| 1994-12-31 | $482.70 Million | +27.03% |
| 1993-12-31 | $380.00 Million | +28.38% |
| 1992-12-31 | $296.00 Million | +45.45% |
| 1991-12-31 | $203.50 Million | +32.75% |
| 1990-12-31 | $153.30 Million | +20.52% |
| 1989-12-31 | $127.20 Million | +21.96% |
| 1988-12-31 | $104.30 Million | +16.28% |
| 1987-12-31 | $89.70 Million | +31.91% |
| 1986-12-31 | $68.00 Million | +43.16% |
| 1985-12-31 | $47.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viatris Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9449.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $3.42 Billion | 18.35% |
| Common Stock | $12.30 Million | 0.07% |
| Other Comprehensive Income | $-3.21 Billion | -17.24% |
| Other Components | $18.42 Billion | 98.83% |
| Total Equity | $18.64 Billion | 100.00% |
Viatris Inc Competitors by Market Cap
The table below lists competitors of Viatris Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EchoStar Corporation
NASDAQ:SATS
|
$15.45 Billion |
|
Entegris Inc
NASDAQ:ENTG
|
$15.47 Billion |
|
Incyte Corporation
NASDAQ:INCY
|
$15.49 Billion |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
$15.49 Billion |
|
Public Bank Bhd
KLSE:1295
|
$15.42 Billion |
|
Rentokil Initial PLC
NYSE:RTO
|
$15.41 Billion |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
$15.39 Billion |
|
Bharat Electronics Limited
NSE:BEL_old
|
$15.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viatris Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,467,400,000 to 18,635,500,000, a change of -1,831,900,000 (-9.0%).
- Net loss of 634,200,000 reduced equity.
- Dividend payments of 574,800,000 reduced retained earnings.
- Share repurchases of 250,000,000 reduced equity.
- New share issuances of 2,500,000 increased equity.
- Other comprehensive income decreased equity by 465,500,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-634.20 Million | -3.4% |
| Dividends Paid | $574.80 Million | -3.08% |
| Share Repurchases | $250.00 Million | -1.34% |
| Share Issuances | $2.50 Million | +0.01% |
| Other Comprehensive Income | $-465.50 Million | -2.5% |
| Other Changes | $90.10 Million | +0.48% |
| Total Change | $- | -8.95% |
Book Value vs Market Value Analysis
This analysis compares Viatris Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 69.60x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.19 | $13.50 | x |
| 1986-12-31 | $0.29 | $13.50 | x |
| 1987-12-31 | $0.36 | $13.50 | x |
| 1988-12-31 | $0.43 | $13.50 | x |
| 1989-12-31 | $0.52 | $13.50 | x |
| 1990-12-31 | $0.60 | $13.50 | x |
| 1991-12-31 | $0.79 | $13.50 | x |
| 1992-12-31 | $1.12 | $13.50 | x |
| 1993-12-31 | $1.41 | $13.50 | x |
| 1994-12-31 | $1.79 | $13.50 | x |
| 1995-12-31 | $2.29 | $13.50 | x |
| 1996-12-31 | $2.38 | $13.50 | x |
| 1997-12-31 | $2.69 | $13.50 | x |
| 1998-12-31 | $3.70 | $13.50 | x |
| 1999-12-31 | $4.11 | $13.50 | x |
| 2000-12-31 | $3.97 | $13.50 | x |
| 2001-12-31 | $4.89 | $13.50 | x |
| 2002-12-31 | $5.12 | $13.50 | x |
| 2003-12-31 | $6.01 | $13.50 | x |
| 2004-12-31 | $6.75 | $13.50 | x |
| 2005-12-31 | $3.36 | $13.50 | x |
| 2006-12-31 | $7.52 | $13.50 | x |
| 2007-12-31 | $13.24 | $13.50 | x |
| 2008-12-31 | $9.06 | $13.50 | x |
| 2009-12-31 | $10.20 | $13.50 | x |
| 2010-12-31 | $10.95 | $13.50 | x |
| 2011-12-31 | $7.96 | $13.50 | x |
| 2012-12-31 | $7.95 | $13.50 | x |
| 2013-12-31 | $7.46 | $13.50 | x |
| 2014-12-31 | $8.18 | $13.50 | x |
| 2015-12-31 | $19.63 | $13.50 | x |
| 2016-12-31 | $21.36 | $13.50 | x |
| 2017-12-31 | $24.80 | $13.50 | x |
| 2018-12-31 | $23.56 | $13.50 | x |
| 2019-12-31 | $23.01 | $13.50 | x |
| 2020-12-31 | $38.18 | $13.50 | x |
| 2021-12-31 | $16.95 | $13.50 | x |
| 2022-12-31 | $17.31 | $13.50 | x |
| 2023-12-31 | $16.96 | $13.50 | x |
| 2024-12-31 | $15.62 | $13.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viatris Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.30%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 2.23x
- Recent ROE (-3.40%) is below the historical average (12.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 43.58% | 25.62% | 1.44x | 1.18x | $15.95 Million |
| 1986 | 34.26% | 24.50% | 1.18x | 1.18x | $16.50 Million |
| 1987 | 28.09% | 26.25% | 0.88x | 1.21x | $16.23 Million |
| 1988 | 17.55% | 20.82% | 0.78x | 1.08x | $7.87 Million |
| 1989 | 20.60% | 27.46% | 0.69x | 1.08x | $13.48 Million |
| 1990 | 21.33% | 35.89% | 0.54x | 1.11x | $17.37 Million |
| 1991 | 19.71% | 30.40% | 0.58x | 1.11x | $19.75 Million |
| 1992 | 23.85% | 33.30% | 0.60x | 1.19x | $41.00 Million |
| 1993 | 19.24% | 29.03% | 0.62x | 1.06x | $35.10 Million |
| 1994 | 25.05% | 30.52% | 0.73x | 1.13x | $72.63 Million |
| 1995 | 16.60% | 26.04% | 0.57x | 1.12x | $40.66 Million |
| 1996 | 9.56% | 14.33% | 0.57x | 1.18x | $-2.87 Million |
| 1997 | 13.54% | 19.07% | 0.62x | 1.14x | $26.35 Million |
| 1998 | 10.89% | 16.00% | 0.60x | 1.14x | $9.41 Million |
| 1999 | 12.81% | 19.52% | 0.59x | 1.11x | $33.87 Million |
| 2000 | 3.28% | 4.39% | 0.58x | 1.29x | $-76.13 Million |
| 2001 | 18.56% | 23.57% | 0.68x | 1.15x | $120.03 Million |
| 2002 | 18.83% | 21.46% | 0.73x | 1.21x | $127.72 Million |
| 2003 | 20.16% | 24.34% | 0.73x | 1.14x | $168.63 Million |
| 2004 | 11.03% | 16.24% | 0.59x | 1.16x | $19.00 Million |
| 2005 | 23.43% | 14.68% | 0.67x | 2.37x | $105.78 Million |
| 2006 | 13.18% | 13.48% | 0.38x | 2.58x | $52.40 Million |
| 2007 | -44.58% | -52.23% | 0.26x | 3.34x | $-1.86 Billion |
| 2008 | -7.11% | -3.82% | 0.49x | 3.77x | $-471.85 Million |
| 2009 | 7.43% | 4.57% | 0.47x | 3.45x | $-80.54 Million |
| 2010 | 9.58% | 6.33% | 0.47x | 3.20x | $-15.07 Million |
| 2011 | 15.37% | 8.76% | 0.53x | 3.32x | $187.63 Million |
| 2012 | 19.18% | 9.43% | 0.57x | 3.57x | $306.78 Million |
| 2013 | 21.20% | 9.03% | 0.45x | 5.20x | $329.52 Million |
| 2014 | 28.55% | 12.04% | 0.49x | 4.86x | $603.81 Million |
| 2015 | 8.68% | 8.99% | 0.42x | 2.28x | $-128.84 Million |
| 2016 | 4.32% | 4.33% | 0.32x | 3.12x | $-631.62 Million |
| 2017 | 5.23% | 5.84% | 0.33x | 2.69x | $-634.76 Million |
| 2018 | 2.90% | 3.08% | 0.35x | 2.69x | $-864.21 Million |
| 2019 | 0.14% | 0.15% | 0.37x | 2.63x | $-1.17 Billion |
| 2020 | -2.92% | -5.61% | 0.19x | 2.68x | $-2.97 Billion |
| 2021 | -6.19% | -7.10% | 0.33x | 2.68x | $-3.32 Billion |
| 2022 | 9.86% | 12.78% | 0.33x | 2.37x | $-28.63 Million |
| 2023 | 0.27% | 0.35% | 0.32x | 2.33x | $-1.99 Billion |
| 2024 | -3.40% | -4.30% | 0.36x | 2.23x | $-2.50 Billion |
Industry Comparison
This section compares Viatris Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viatris Inc (VTRS) | $15.22 Billion | 43.58% | 1.49x | $15.45 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |